



Study of High Gamma Glutamyl Transferase Cholestasis In Egyptian Children

Thesis

*Submitted For Partial Fulfillment of M.Sc.
Degree In Paediatrics*

By

Hani Abd-Elsalam Hasan Khedr

M.B.B.Ch, Ain shams university (2010)

Under Supervision Of

Prof. Tawheda Yassin Abdel-Ghaffar

Professor of Paediatric Hepatology

Faculty of Medicine - Ain Shams University

Prof. Solaf Mohamed Elsayed

Professor of Medical Genetics

Faculty of Medicine - Ain Shams University

Dr. Asmaa Wafeeq Abdel-Aziz

Lecturer of Pediatrics

Faculty of Medicine - Ain Shams University

*Faculty of Medicine
Ain Shams University*

2019

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

سَبِّحْكَ لَا إِلَهَ إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I wish to express my deepest thanks, gratitude and appreciation to **Prof. Dr. Yassin Abdel-Ghaffar** Charity Center for Liver Disease and Research, for giving me the chance to obtain the required data about the patients and follow up them.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Jawheda Yassin Abdel-Ghaffar**, Professor of Paediatric Hepatology Faculty of Medicine - Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Prof. Solaf Mohamed Elsayed**, Professor of Medical Genetics Faculty of Medicine - Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Dr. Asmaa Wafeeq Abdel-Aziz**, Lecturer of Pediatrics Faculty of Medicine - Ain Shams University, for her great help, active participation and guidance.*

Hani Khedr

List of Contents

Title	Page No.
List of Tables	5
List of Figures	7
List of Abbreviations	9
Introduction	1
Aim of the Work.....	14
Review of Literature	
▪ Gamma-Glutamyl Transferases	15
▪ Cholestatic Liver Disease in Children.....	21
▪ Progressive Familial Intrahepatic Cholestasis	41
▪ Alagille Syndrome	63
Subjects and Methods	83
Results	90
Discussion	124
Limitations of the Study	137
Summary	138
Conclusion.....	142
Recommendations	143
References	144
Arabic Summary	—

List of Tables

Table No.	Title	Page No.
Table (1):	Mechanisms of Cholestasis of Sepsis	38
Table (2):	Characteristics of progressive familial intrahepatic cholestasis.	45
Table (3):	Laboratory parameters aiding in the diagnosis of PFIC.....	47
Table (4):	Suggested daily vitamin and mineral supplementation.	54
Table (5):	Summary of molecular genetic testing used in ALGS.	65
Table (6):	Classic Criteria, based on five body systems, for a diagnosis of Alagille syndrome.	68
Table (7):	Diagnosis of the studied patients.	91
Table (8):	Demographic data of the studied patients.....	91
Table (9):	Anthropometric measures of the studied group Weight for Age Percentiles	92
Table (10):	Height /Length for Age percentiles.	93
Table (11):	Body mass index for age percentiles.	94
Table (12):	Clinical picture at presentation and last follow up among the studied patients	95
Table (13):	Investigations of PFIC3 patients at presentation and at last follow up.	98
Table (14):	Investigations of Alagille patients at presentation and at last follow up.	101
Table (15):	Comparison between investigations of PFIC3 patients and Alagille syndrome patients at presentation and last follow up.....	104

List of Tables Cont...

Table No.	Title	Page No.
Table (16):	Comparison between investigations of PFIC3 patients and Alagille syndrome patients at last follow up	105
Table (17):	Ultrasonography of PFIC3 patients	106
Table (18):	Ultrasonography of the Alagille patients.....	107
Table (19):	Other investigations among the studied patients at presentation and at last follow up.....	108
Table (20):	Liver biopsy among the studied patients at presentation.....	110
Table (21):	Treatment of the studied patients (Both PFIC3 and alagille patients).....	111
Table (22):	CHILD score of the studied patients at presentation and last follow up.....	113
Table (23):	Summary of the outcome of the studied group.....	114
Table (24):	Comparison between the CHILD score at last follow up and the below mentioned parameters at presentation for PFIC3 patients.....	116
Table (25):	Univariate logistic regression analysis for predictors of poor outcome in PFIC3 patients	117
Table (26):	Comparison between the CHILD score at last follow up and the below mentioned parameters at presentation for Alagille patients	120
Table (27):	Univariate logistic regression analysis for predictors of poor outcome in Alagille patients.....	122

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Triangular-cord-sign of BA	26
Figure (2):	Alagille syndrome.....	28
Figure (3):	Diagnostic algorithm for neonatal cholestasis.	40
Figure (4):	Etiopathogenesis of PFIC.....	42
Figure (5):	Histomorphological pointers to suspect a case of progressive familial intrahepatic cholestasis.....	49
Figure (6):	Biliary drainage procedures	57
Figure (7):	Posterior embryotoxon	72
Figure (8):	Butterfly vertebrae seen in the thoracic and upper lumbar regions	73
Figure (9):	The hands of the child	73
Figure (10):	a) Characteristic facial features seen in ALGS. b) Face profile figure, c) Intra-oral frontal figure.....	74
Figure (11):	Flow diagram of genetic investigations and management for suspected ALGS patients	79
Figure (12):	Relation between the outcome at last follow up and S. total bilirubin at presentation in PFIC3 Patients.	118
Figure (13):	Relation between the outcome at last follow up and S. direct bilirubin in PFIC3 Patients..	118
Figure (14):	Relation between the outcome at last follow up and S.GGT at presentation in PFIC3 Patients.	119
Figure (15):	Relation between the outcome at last follow up and S.albumin at presentation in PFIC3 Patients.....	119

List of Figures Cont...

Fig. No.	Title	Page No.
Figure (16):	Relation between the outcome at last follow up and INR at presentation in Alagille patients.....	122
Figure (17):	Relation between the outcome at last follow up and	123

List of Abbreviations

Abb.	Full term
<i>3βHSD</i>	<i>3β-hydroxy-C27-steroid oxidoreductase (dehydrogenase / isomerase) deficiency</i>
<i>5βRD</i>	<i>5β-reductase</i>
<i>A1ATD</i>	<i>Alpha1-antitrypsin deficiency</i>
<i>ABE</i>	<i>Acute bilirubin encephalopathy</i>
<i>ALGS</i>	<i>Alagille syndrome</i>
<i>ALP</i>	<i>Alkaline phosphatase</i>
<i>ALT</i>	<i>Alanine aminotransferase</i>
<i>ARC</i>	<i>Arthrogryposis- renal dysfunction cholestasis</i>
<i>ARPKD</i>	<i>Autosomal recessive polycystic kidney disease</i>
<i>AS</i>	<i>Alagille syndrome</i>
<i>ASD</i>	<i>Atrial septal defect</i>
<i>AST</i>	<i>Aspartate aminotransferase</i>
<i>BA</i>	<i>Biliary atresia</i>
<i>BPA st.</i>	<i>Branch pulmonary artery stenosis</i>
<i>BRIC</i>	<i>Benign Recurrent Intrahepatic Cholestasis</i>
<i>BSEP</i>	<i>Bile salt export pump</i>
<i>CA</i>	<i>Cholic acid</i>
<i>CB</i>	<i>Conjugated bilirubin</i>
<i>CDCA</i>	<i>Chenodeoxycholic acid</i>
<i>CFR</i>	<i>Case fatality rate</i>
<i>CLS</i>	<i>Cholestasis-lymphedema syndrome</i>
<i>CMV</i>	<i>Congenital cytomegalovirus</i>
<i>DB</i>	<i>Direct bilirubin</i>
<i>ESLD</i>	<i>End stage liver disease</i>
<i>FAB-MS</i>	<i>Fast atom bombardment-mass spectrometry</i>
<i>FISH</i>	<i>Fluorescence in situ hybridization</i>
<i>GC-MS</i>	<i>Gas chromatography-mass spectrometry</i>

List of Abbreviations Cont...

Abb.	Full term
<i>GGT</i>	<i>Gamma glutamyl transferase</i>
<i>Hb</i>	<i>Hemoglobin</i>
<i>HBS</i>	<i>Hepatobiliary scintigraphy</i>
<i>HCC</i>	<i>Hepatocellular carcinoma</i>
<i>IB</i>	<i>Ileal bypass</i>
<i>IL-6</i>	<i>Interleukin 6</i>
<i>KCs</i>	<i>Kupffer cells</i>
<i>LT</i>	<i>Liver transplantation</i>
<i>MARS</i>	<i>Molecular Adsorbent Recirculating System</i>
<i>MDR3</i>	<i>Multidrug resistance 3 protein</i>
<i>NAIC</i>	<i>North American Indian Childhood Cirrhosis</i>
<i>NBD</i>	<i>Nasobiliary drainage</i>
<i>NC</i>	<i>Neonatal cholestasis</i>
<i>NICU</i>	<i>Neonatal ICU</i>
<i>NNJ</i>	<i>Neonatal jaundice</i>
<i>NO</i>	<i>Nitric oxide</i>
<i>NP-C</i>	<i>Niemann-Pick disease</i>
<i>PEBD</i>	<i>Partial external biliary drainage</i>
<i>PFIC</i>	<i>Progressive Familial Intrahepatic Cholestasis</i>
<i>pGp</i>	<i>p-glycoprotein</i>
<i>PIBD</i>	<i>Partial internal biliary drainage</i>
<i>PSC</i>	<i>Primary sclerosing cholangitis</i>
<i>PV</i>	<i>Portal vein</i>
<i>PVS</i>	<i>Pulmonary valve stenosis</i>
<i>RDA</i>	<i>Recommended daily allowance</i>
<i>RES</i>	<i>Reticuloendothelial system</i>
<i>SI</i>	<i>Suspicion Index</i>
<i>SNHL</i>	<i>Sensorineural hearing loss</i>

List of Abbreviations Cont...

Abb.	Full term
<i>TB</i>	<i>Total bilirubin</i>
<i>TNF-α</i>	<i>Tumor necrosis factor alpha</i>
<i>TOF</i>	<i>Tetralogy of Fallot</i>
<i>TORCH</i>	<i>Toxoplasmosis, rubella, cytomegalovirus, herpes simplex</i>
<i>UDCA</i>	<i>Ursodeoxycholic acid</i>
<i>VSD</i>	<i>Ventricular septal defect</i>
<i>WBCs</i>	<i>White blood cells</i>
<i>ZO-2</i>	<i>Zona occludens 2</i>

INTRODUCTION

During early life, failure of secretion of both bile and conjugated bilirubin is the commonest manifestation of liver dysfunction. Jaundice is frequently a feature of early rather than late advanced liver disease as is seen in older children (*Bezerra and Balistreri, 2001*).

Cholestasis is defined as a decrease in bile flow due to impaired secretion by hepatocytes or due to obstruction of bile flow through intra or extrahepatic bile ducts (*Nazer, 2014*). It is also defined biochemically as a direct bilirubin greater than 2 mg/dl or more than 20% of the total bilirubin (*Venigalla and Gourley, 2004*). Hyperbilirubinemia characterized by jaundice, acholic stool, dark urine and hepatomegaly must always be considered as a pathological state (*Suchy, 2004*).

Gamma glutamyl transferase (GGT) is an enzyme found in cell membranes of many tissues mainly in the liver, in both the hepatocytes and bile ducts. It is also found in the intestine, spleen, heart, brain, and seminal vesicles, but the liver is considered the source of normal enzyme activity. GGT levels are increased in patients with liver diseases in general, including cholestasis (*Davit-Spraul et al., 2010*).

The differential diagnosis of high GGT in the category of infantile cholestasis is extensive and can be classified based on the anatomic location of pathology into extrahepatic and

intrahepatic aetiologies. Biliary atresia, choledochal cyst, bile duct stenosis, primary sclerosing cholangitis, choledochal pancreatico- ductal anomaly and neoplasm are examples of extrahepatic causes while, idiopathic neonatal hepatitis, progressive familial intrahepatic cholestasis type 3, Alagille syndrome are common intrahepatic etiologies (*Fischler et al., 2007; Nguyen et al., 2014*).

In a recent study the predictive parameters of unfavorable outcome of intrahepatic cholestasis at presentation included etiology, age of onset, positive consanguinity and itching, where at 3rd month of follow-up they included enlarged firm liver, persistently pale stool, high ALT and AST. At one year, outcome could be predicted by the presence or absence of splenomegaly and low serum albumin (*Abdel-Ghaffar et al., 2014*).

AIM OF THE WORK

The aim of this study was to evaluate patients with high GGT non surgical cholestasis as regard their different aetiologies, demograhic characteristics, clinical picture and outcome.

*Chapter One***GAMMA-GLUTAMYL TRANSFERASES**

Gamma glutamyl transferases (GGT) are highly conserved enzymes that occur in bacteria, yeast, plants and in animals from nematodes to humans (*Rawlings et al., 2006*). It is a two substrate enzyme that removes the terminal γ - glutamyl residue from a molecule of the general form Glu- γ CO-NH-R by breaking the amide bond and transfers it to receptive molecule. Some of the common physiological γ -glutamyl substrates are glutathione (*Elce and Broxmeyer, 1976*), γ -poly glutamic acid (*Kimura et al., 2004*) and glutamine (*Minami et al., 2003*).

Sites of production

GGT is found mainly in the membranes of cells that show high secretory or absorptive capacity: the epithelial cells lining the biliary tract, hepatic canaliculi, proximal renal tubules, pancreatic acinar tissue, pancreatic ductules, and intestinal brush border cells (*Rawlings et al., 2006*)

GGT bioclinical conditions

GGT levels in blood are routinely measured in clinical laboratories. Indeed, GGT in serum is mainly derived from the liver, thus the enzyme is used as marker of liver or biliary tract-associated diseases. The higher the GGT level the greater the “insult” to the liver. Serum levels of GGT are affected by